摘要：SummaryThe phenotype of β-thalassemia underlies multigene interactions, making clinical stratification complicated. An increasing number of genetic modifiers affecting the disease severity have been identified, but are still unable to meet the demand of precision diagnosis. Here, we systematically conducted a comparative plasma proteomic profiling on patients with β-thalassemia and healthy controls. Among 246 dysregulated proteins, 13 core protein signatures with excellent biomarker potential are proposed. The combination of proteome and patients' clinical data revealed patients with codons 41/42 -TTCT mutations have an elevated risk of higher iron burden, dysplasia, and osteoporosis than patients with other genotypes. Notably, 85 proteins correlating to fetal hemoglobin (Hb F) were identified, among which the abundance of 27 proteins may affect the transfusion burden in patients with β-thalassemia. The current study thus provides protein signatures as potential diagnostic biomarkers or therapeutic clues for β-thalassemia.Graphical abstractDisplay OmittedHighlights•246 dysregulated proteins are detected in plasma of patients with β-thalassemia•13 potential biomarkers and 27 proteins related to disease progression are found•Variations in plasma proteome reveal the disease pathophysiological characteristics•Codons 41/42 -TTCT carriers have higher ferritin levels compared to non-carriersHealth sciences; Omics; Proteomics
